Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Gentian Diagnostics ASA ( (DE:6FK) ).
Gentian Diagnostics ASA is a Norway-based developer and manufacturer of high-quality in vitro diagnostic reagents, specializing in immunoassays for infections, inflammation, kidney disease and heart failure, and serving both human and veterinary diagnostics markets globally from its Moss headquarters and international offices in Sweden, the USA and China. The company will host an educational webinar on 25 February 2026 focused on NT-proBNP, a key biomarker for heart failure, featuring leading cardiology and pathology experts who will discuss current clinical use and analytical challenges such as the impact of glycosylation on assay performance, underscoring Gentian’s commitment to scientific outreach and its NT-proBNP development program, with a recorded version to be made available after the event.
More about Gentian Diagnostics ASA
Gentian Diagnostics ASA is a Norway-based developer and manufacturer of high-quality in vitro diagnostic reagents, specializing in immunoassays for infections, inflammation, kidney disease and heart failure. By converting established, clinically relevant biomarkers to high-throughput analyser formats, the company aims to improve diagnostic efficiency and treatment decisions, serving global human and veterinary diagnostics markets from its headquarters in Moss with additional presence in Sweden, the USA and China.
Average Trading Volume: 9,920
Current Market Cap: NOK894.5M
For an in-depth examination of 6FK stock, go to TipRanks’ Overview page.